Recent advancements in ropinirole hydrochloride embedded nano-techniques in Parkinson’s treatment

Abstract

Parkinson's Disease (PD) is effecting 7-10 million people of worldwide as the report of WHO 2014. It has proved to be 2^nd most a neuro-degenerative disorder of the central nervous system (CNS). It occurs due to the death of dopamine-generating cells in the substantia-nigra, a region of the midbrain. It is characterized by tremor, rigidity, bradykinesia, dementia, depression and falls or emerges with the progression of the disease. Ropinirole HCl is a low molecular weight, highly water soluble drug. It is rapidly absorbed from the G.I.T and mean peak plasma concentrations have been achieved within 1.5 h after oral doses. The oral bioavailability of Ropinirole HCl is 50% due to extensive first pass metabolism by the liver. Its mean plasma half-life is 5–6 h. The present study tries to enlighten the prior art related to Parkinson's treatment and to prepare Ropinirole HCl loaded Nano-structured lipid carriers (NLC) that may overcome the problem of bioavailability and bypass the blood brain barrier by preparing the intra-nasal drug delivery targeted to the brain thereby decreasing the dosing frequency and increasing patient compliance.